NCT01433887

Response to Pegylated Interferon and Ribavirin in Chinese Patients With Chronic Hepatitis C Genotypes 1 Versus 2/3 Versus 6

Response to Pegylated Interferon and Ribavirin in Chinese Patients With Chronic

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 535 (actual)
• Sponsor: Third Affiliated Hospital, Sun Yat-Sen University · Academic / Other
• Sex: All
• Age: 16 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The Chinese patients with chronic hepatitis C have a different genetic background, which had been demonstrated to significantly influence their responses to pegylated interferon and ribavirin. In this study, Chinese patients with Hepatitis C Virus genotype 1, 2/3, 6 infection were treated with pegylated interferon and ribavirin. Their response was compared amongst different genotypes.

Conditions

• Chronic Hepatitis C

Interventions

Type	Name	Description
DRUG	48-weeks course	patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
DRUG	Ribavirin	patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
DRUG	Peginterferon alfa2a	patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
DRUG	Ribavirin	patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks

Timeline

• Start date: 2011-11-01
• Primary completion: 2014-06-01
• Completion: 2014-06-01
• First posted: 2011-09-14
• Last updated: 2014-11-18

Locations

3 sites across 1 country: China